Stellular Bio

Executive Summary

Stellular Bio is a preclinical-stage biotechnology company pioneering a novel Platelet-derived Regenerative Biologic (PRB) therapy for ocular surface diseases (OSD). Founded in 2021 and headquartered in Cambridge, Massachusetts, the company is developing STLR-201, an engineered biologic that harnesses the regenerative properties of platelets to address the underlying pathology of Sjogren's syndrome-related dry eye. Current treatments for Sjogren's dry eye focus on symptomatic relief via artificial tears or anti-inflammatory agents, but they fail to restore the damaged ocular surface. STLR-201 aims to promote tissue repair and regeneration, potentially offering a disease-modifying approach. The company's technology represents a shift from conventional therapies toward regenerative medicine in ophthalmology. Although Stellular Bio remains in the preclinical phase, the unmet need in Sjogren's dry eye is substantial, affecting millions worldwide with limited effective options. The PRB platform could be extended to other ocular surface diseases, broadening its market potential. However, the early stage of development introduces significant technical and regulatory risks. Success will depend on generating robust preclinical data, securing intellectual property, and advancing STLR-201 into clinical trials. The company's progress over the next 12–18 months will be critical in establishing its therapeutic value and attracting further investment or partnerships.

Upcoming Catalysts (preview)

• Q4 2026IND filing for STLR-20140% success
• Q3 2026Publication of preclinical efficacy data60% success
• Q2 2026Series A financing or strategic partnership30% success